about
Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trialComparison of real-time multiplex human papillomavirus (HPV) PCR assays with the linear array HPV genotyping PCR assay and influence of DNA extraction method on HPV detectionComparison of real-time multiplex human papillomavirus (HPV) PCR assays with INNO-LiPA HPV genotyping extra assay.Incidence and predictors of human papillomavirus-6, -11, -16, and -18 infection in young norwegian women.Development of a human papillomavirus competitive luminex immunoassay for 9 HPV typesThe impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years.The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years.Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine - A combined analysis of five phase III clinical trials.Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial.Safety and Immunogenicity of an Anti-Zika Virus DNA Vaccine - Preliminary Report.Concordance assessment between a multiplexed competitive Luminex immunoassay, a multiplexed IgG Luminex immunoassay, and a pseudovirion-based neutralization assay for detection of human papillomaviruse types 16 and 18.Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.Evaluation of the HPV 18 antibody response in Gardasil® vaccinees after 48 mo using a pseudovirion neutralization assay.Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection.ZIKA-001: Safety and Immunogenicity of an Engineered DNA Vaccine Against ZIKA virus infection.Comparison of HPV genotypes and viral load between different sites of genital tract: the significance for cervical cancer screening.Importance of specimen type in detecting human papillomavirus DNA from the female genital tract.HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine.Detection of HPV in Norwegian cervical biopsy specimens with type-specific PCR and reverse line blot assays.Zika-Induced Male Infertility in Mice Is Potentially Reversible and Preventable by Deoxyribonucleic Acid ImmunizationA Pooled Analysis of Continued Prophylactic Efficacy of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine against High-grade Cervical and External Genital LesionsAssay Challenges for Emerging Infectious Diseases: The Zika ExperienceImmunogenicity and safety of an investigational tetravalent recombinant subunit vaccine for dengue: results of a Phase I randomized clinical trial in flavivirus-Naïve adultsEmerging infectious disease laboratory and diagnostic preparedness to accelerate vaccine development
P50
Q28750269-7E8FA8F7-0F04-402F-A2A5-90BD39D9851FQ35066537-72121247-D253-4FD0-B218-86EF8A1D05FEQ35066675-2DE5B372-6A5C-4935-B5C5-0C97634FD4B6Q37851411-FF6F2547-3337-4DB0-B84C-43256348EBEFQ38271441-65097139-C9BC-482A-ACFD-C778BBB44C97Q38383523-CD77CAD9-BF82-45C1-B882-F06E0CFC2E92Q38383530-78787D8F-15EC-4C4B-B4FC-119962C3D603Q38673370-1022EF59-C152-47C3-BAA0-BA90341FBF20Q40050396-C8C3C3B7-6746-4AC6-964D-CDD9A3162FA2Q41924763-553FC2F2-7F78-4B50-BFB1-B480EB9983FBQ42198454-2E8A4FD8-0D77-4C37-B8E1-C41A851712C3Q43655015-2BD11934-20DB-404E-AFAC-0310F2DD845BQ44539557-7A9C7854-7EE4-4223-95D2-FB3E6586E9D5Q46654947-C0835B95-018D-4B81-8AF4-C9730A1E1598Q47147175-7FEB6D80-14DE-4EF1-A8CE-A41B8D6E1F2FQ51161206-B4E25190-92E1-41A5-90BF-0F74268CFE98Q51624778-DD37DF7C-1AFC-4EBF-93B9-B9CFA51E0FCAQ51961251-98225AC7-0DBC-4EF1-BF13-4788EC61F556Q54597496-7E1F9952-5286-43E5-85DC-9B321586DB88Q56343708-EAD11A9B-A2EA-43C7-97AE-AA74574898A9Q56770293-F28B0C27-FE91-4175-B89C-7898BB8DDF89Q59452480-8158E2FA-3AF7-46EC-BD37-FEE4CB215186Q60187976-6DF410C0-B135-4C32-A455-28326B258EA1Q91576851-8E1AD92A-2441-4C52-A4B3-2773982A9B7B
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Christine C Roberts
@ast
Christine C Roberts
@en
Christine C Roberts
@es
Christine C Roberts
@nl
Christine C Roberts
@sl
type
label
Christine C Roberts
@ast
Christine C Roberts
@en
Christine C Roberts
@es
Christine C Roberts
@nl
Christine C Roberts
@sl
prefLabel
Christine C Roberts
@ast
Christine C Roberts
@en
Christine C Roberts
@es
Christine C Roberts
@nl
Christine C Roberts
@sl
P106
P21
P31
P496
0000-0003-4359-7946